Pure Global
NCT04900220

Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections

Investigating Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections Using Betamethasone and Methylprednisolone
West Virginia University·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Trigger Finger
Drug/Device/Intervention
Betamethasone
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
West Virginia University
Location
Morgantown,Morgantown, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Sep 15, 2021
End date
Dec 01, 2022
Enrollment
100 participants
Primary outcome

Incidence of pain,Intensity of pain,Peak of flare reaction,Resolution of flare reaction

Summary

Two common corticosteroids used for trigger finger treatment are betamethasone and
 methylprednisolone. Both injections are effective in treating trigger finger and the decision
 of which to use in treatment is currently a matter of the current practice and physician
 preference. The goal through this randomized trial is to see whether there is a difference
 between these two corticosteroids in inducing flare reactions and if there are any
 differences in the peak level of pain and their duration. Findings indicating a statistically
 significant difference in the incidence and/or intensity of the flare reactions would be
 clinically significant and would be evidence supporting the switch of current practice to one
 corticosteroid over the other.

ICD-10 classifications
Trigger fingerAccessory finger(s)Fused fingersAccessory thumb(s)Clubbing of fingers
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04900220
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04900220 through Pure Global AI's free database. This Phase 4 trial is sponsored by West Virginia University and is currently Recruiting. The study focuses on Trigger Finger. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.